Bibliometric Analysis and Visualization of Research Progress in the Diabetic Nephropathy Field from 2001 to 2021

Shao, Ying; Shi, Xiaoguang

doi:10.1155/2023/4555609

Cited by 3 publications

(1 citation statement)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found PVGs on the topics of obesity and diabetes that re ect the evidence basis of almost 7 or 6 years ago [26,28,48]. According to bibliometric analyses, there is an upward trend in the number of publications in different elds of diabetes [73][74][75]. Therefore, it may be considered whether these PVGs re ect the current state of knowledge and whether patients may bene t from them.…”

Section: Discussionmentioning

confidence: 93%

Up-to-dateness of patient versions of clinical practice guidelines and potential influencing factors: a mixed-methods analysis

Hellbrecht,

Könsgen,

Pieper

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Clinical practice guidelines (CPGs) provide recommendations and are a fundamental part of clinical practice. Following and based on CPGs, many guideline organisations also produce patient versions of CPGs (PVGs). The main objective of this study was to perform a mixed-methods analysis on the up-to-dateness of German PVGs and potential methodological influence factors. Methods: A mixed-methods analysis was conducted. First, a literature search to identify PVGs was performed between October 2022 and January 2023. PVGs fulfilling the following criteria were included: published in German, free accessible, explicit link to corresponding CPG, final version, date of literature search of CPG and publication date of PVG available (no publication date restriction). Second, interviews with experts in the PVG development were conducted and analysed using qualitative content analysis (following Mayring) with MAXQDA software. Results: 49 PVGs were included and analysed. A median of 36 months elapsed between the literature search of CPGs and the publication of PVGs. Six interviews were conducted and interviewees mostly perceived PVGs as up-to-date. However, they identified exceptions in the up-to-dateness depending on the topic or thematic chapters of PVGs. Interviewees mentioned different influencing factors such as the scientific progress and the editorial process of PVGs. Conclusion: Our findings shed light on potential issues with regard to the up-to-dateness of PVGs. In the context of a fast-moving evidence basis, it seems doubtful whether PVGs actually reflect the current state of knowledge, especially in fields with high research activity. However, some factors may not be modifiable because they essentially contribute to the quality assurance of PVGs. Further research is desirable to investigate which measures may be feasible to improve the up-to-dateness of PVGs.

show abstract

Section: Discussionmentioning

confidence: 93%

Up-to-dateness of patient versions of clinical practice guidelines and potential influencing factors: a mixed-methods analysis

Hellbrecht,

Könsgen,

Pieper

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Digital Twin and Extended Reality in Industrial Contexts: A Bibliometric Review

Del Vecchio,

Lazoi,

Lezzi

2023

Lecture Notes in Computer Science

View full text Add to dashboard Cite

Nephroprotective effect of cranberry (Vaccinium oxycoccos) in streptozocin-induced diabetic nephropathy in mice

Shareef,

Khaleel,

Maryoosh

2024

Drug Metabolism and Personalized Therapy

View full text Add to dashboard Cite

Objectives Diabetic nephropathy is a chief reason of mortality particularly in individuals with renal dysfunction. The current research was aimed to assess the nephroprotective portion of Vaccinium oxycoccos toward mice diabetic nephropathy induced by streptozotocin (STZ). V. oxycoccos was purchased and used for hydroalcoholic extraction. Methods Sixty male mice were subjected to STZ-intraperitoneal injection (45 mg/kg). After diabetes induction, mice were divided into five groups of diabetic control (received only STZ), non-diabetic control (received only citrate buffer), two V. oxycoccos treatment (received V. oxycoccos extract (200 and 400 mg/kg) oral daily by gavage), and metformin treatment (received metformin (500 mg/kg) oral daily by gavage). Glucose and weight of mice were checked weekly. Results After 28 days, the effect of V. oxycoccos extract on serum and urine parameters were assessed. STZ caused significant decreased in the mice body weight. Mice treated with the V. oxycoccos (400 mg/kg) harbored the lowest weight loss at day 28 (70.2±1.38 g). STZ caused significant increase in the mice FBS. Mice treated with the V. oxycoccos (400 mg/kg) harbored the lowest FBS at day 28 (189.2±1.20 mg/dL). Treatment of mice with V. oxycoccos (400 mg/kg) caused the lowest increase in the levels of cholesterol, HbA1c and triglycerides compared to the diabetic control mice. Compared to the diabetic control group, mice treated with V. oxycoccos (400 mg/kg) had the highest HDL, insulin, SOD, and GSH (p<0.05). The lowest serum BUN, CR, and UR were found in mice treated with V. oxycoccos (400 mg/kg). Anti-inflammatory effects of V. oxycoccos (400 mg/kg) was shown by the lowest TNF-α, IL-6, and TGF-β1 concentration in mice treated with V. oxycoccos (400 mg/kg). Conclusions The current study disclosed that treatment with V. oxycoccos resulted in substantial development in the serum and urine parameters and also antioxidant and anti-inflammatory response of STZ-induced diabetic mice.

show abstract

Bibliometric Analysis and Visualization of Research Progress in the Diabetic Nephropathy Field from 2001 to 2021

Cited by 3 publications

References 55 publications

Up-to-dateness of patient versions of clinical practice guidelines and potential influencing factors: a mixed-methods analysis

Up-to-dateness of patient versions of clinical practice guidelines and potential influencing factors: a mixed-methods analysis

Digital Twin and Extended Reality in Industrial Contexts: A Bibliometric Review

Nephroprotective effect of cranberry (Vaccinium oxycoccos) in streptozocin-induced diabetic nephropathy in mice

Contact Info

Product

Resources

About